KCM
ITOS

Kennedy Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Kennedy Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-154,717
Closed -$924K – 633
2025
Q1 		$924K Buy
154,717
+16,126
+12% +$118K 0.02% 526
2024
Q4 		$1.06M Sell
138,591
-16,844
-11% -$145K 0.02% 590
2024
Q3 		$1.59M Buy
155,435
+5,185
+3% +$79.1K 0.04% 545
2024
Q2 		$2.23M Buy
150,250
+4,516
+3% +$64.7K 0.05% 495
2024
Q1 		$1.99M Buy
+145,734
New +$1.59M 0.04% 520

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kennedy Capital Management's ITOS Position: Q2 2025 in Review

Kennedy Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 154,717 shares — an estimated $924K sold.

Kennedy Capital Management first reported a position in ITOS in Q1 2024 and held it in 5 quarters. The position peaked at $2.23M in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Kennedy Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 154,717 iTeos Therapeutics shares in Q2 2025, an estimated $924K.
  • Kennedy Capital Management first reported a position in iTeos Therapeutics in Q1 2024 and held it in 5 quarters.
  • Kennedy Capital Management's iTeos Therapeutics position peaked at $2.23M in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Kennedy Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.